(-)-epigallocatechin 3-gallate increases expression EXP 6480464 epigallocatechin gallate results in increased expression of AKR1C1 mRNA CTD PMID:32512070 (1S)-bornane-2,3-dione increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of camphorquinone CTD PMID:16508162 (E)-cinnamyl alcohol increases expression EXP 6480464 cinnamyl alcohol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 (S)-naringenin multiple interactions EXP 6480464 naringenin binds to and results in decreased activity of AKR1C1 protein CTD PMID:16962702 1,10-phenanthroline decreases activity EXP 6480464 1, 10-phenanthroline results in decreased activity of AKR1C1 protein CTD PMID:12604236 , PMID:8573067 1,7-phenanthroline decreases activity EXP 6480464 1, 7-phenanthroline results in decreased activity of AKR1C1 protein CTD PMID:8573067 1-chloro-2,4-dinitrobenzene increases expression EXP 6480464 Dinitrochlorobenzene results in increased expression of AKR1C1 mRNA CTD PMID:20566472 1-naphthyl isothiocyanate decreases expression ISO RGD:1306847 6480464 1-Naphthylisothiocyanate results in decreased expression of AKR1C1 mRNA CTD PMID:25380136 16-Ketoestrone increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of 16-ketoestrone CTD PMID:16508162 17beta-estradiol multiple interactions EXP 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of AKR1C1 mRNA CTD PMID:19619570 17beta-estradiol increases expression EXP 6480464 Estradiol results in increased expression of AKR1C1 mRNA CTD PMID:19619570 17beta-hydroxy-5alpha-androstan-3-one multiple interactions EXP 6480464 Flufenamic Acid inhibits the reaction [AKR1C1 protein results in increased metabolism of Dihydrotestosterone] CTD PMID:14672942 17beta-hydroxy-5alpha-androstan-3-one increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of Dihydrotestosterone CTD PMID:16508162 17beta-hydroxy-5alpha-androstan-3-one increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of Dihydrotestosterone CTD PMID:14672942 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1614979 6480464 2 more ... CTD PMID:21851831 , PMID:25510870 2,2',4,4',5,5'-hexachlorobiphenyl decreases expression ISO RGD:1614979 6480464 2 more ... CTD PMID:20005886 , PMID:21851831 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1614979 6480464 [2 more ... CTD PMID:25510870 2,3,7,8-tetrachlorodibenzodioxine multiple interactions EXP 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of AKR1C1 mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1614979 6480464 2 more ... CTD PMID:21851831 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1614979 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR1C20 mRNA CTD PMID:20005886 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1306847 6480464 Tetrachlorodibenzodioxin affects the expression of AKR1C1 mRNA CTD PMID:22298810 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1306847 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR1C1 mRNA, Tetrachlorodibenzodioxin results in decreased expression of AKR1C6 mRNA CTD PMID:18796159 , PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR1C1 mRNA CTD PMID:19619570 2,3-dimethoxynaphthalene-1,4-dione increases expression EXP 6480464 2 more ... CTD PMID:9973208 2,6-dinitrotoluene affects expression ISO RGD:1306847 6480464 2, 6-dinitrotoluene affects the expression of AKR1C6 mRNA CTD PMID:21346803 2-hydroxypropanoic acid increases expression EXP 6480464 Lactic Acid results in increased expression of AKR1C1 mRNA CTD PMID:20566472 , PMID:30851411 2-tert-butylhydroquinone increases expression EXP 6480464 2-tert-butylhydroquinone results in increased expression of AKR1C1 mRNA CTD PMID:30806763 , PMID:9973208 3,3',4,4',5-pentachlorobiphenyl multiple interactions ISO RGD:1306847 6480464 [3 more ... CTD PMID:30744511 3,3',5-triiodo-L-thyronine increases expression EXP 6480464 Triiodothyronine results in increased expression of AKR1C1 mRNA CTD PMID:15507505 3,4,5,3',4',5'-Hexachlorobiphenyl multiple interactions ISO RGD:1306847 6480464 [3 more ... CTD PMID:30744511 3,4-dichloroaniline increases expression EXP 6480464 3, 4-dichloroaniline results in increased expression of AKR1C1 mRNA CTD PMID:24172598 3-isobutyl-1-methyl-7H-xanthine multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of AKR1C1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AKR1C1 mRNA CTD PMID:28628672 3-methylcholanthrene increases expression EXP 6480464 Methylcholanthrene results in increased expression of AKR1C1 mRNA CTD PMID:9973208 3-Nitrobenzanthrone increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of 3-nitrobenzanthrone CTD PMID:30406992 3-Nitrobenzanthrone multiple interactions EXP 6480464 [AKR1C1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of 3-aminobenzanthrone, [AKR1C1 protein results in increased reduction of 3-nitrobenzanthrone] which results in increased chemical synthesis of N-hydroxy-3-aminobenzanthrone CTD PMID:30406992 3-phenylprop-2-enal increases expression EXP 6480464 cinnamaldehyde results in increased expression of AKR1C1 mRNA CTD PMID:19524605 3alpha-hydroxy-5beta-pregnan-20-one increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of Pregnanolone CTD PMID:11995921 3alpha-hydroxy-5beta-pregnan-20-one affects metabolic processing EXP 6480464 AKR1C1 protein affects the metabolism of Pregnanolone CTD PMID:12604236 4,4'-diaminodiphenylmethane decreases expression ISO RGD:1306847 6480464 4, 4'-diaminodiphenylmethane results in decreased expression of AKR1C1 mRNA CTD PMID:25380136 4,4'-diaminodiphenylmethane increases expression ISO RGD:1614979 6480464 4, 4'-diaminodiphenylmethane results in increased expression of AKR1C20 mRNA CTD PMID:18648102 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of AKR1C1 mRNA CTD PMID:28628672 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone CTD PMID:11306090 4-hydroxybenzoic acid decreases activity EXP 6480464 4-hydroxybenzoic acid analog results in decreased activity of AKR1C1 protein CTD PMID:27163852 4-hydroxyphenyl retinamide increases expression EXP 6480464 Fenretinide results in increased expression of AKR1C1 mRNA CTD PMID:16671099 4-phenylbutyric acid increases expression EXP 6480464 4-phenylbutyric acid results in increased expression of AKR1C1 mRNA CTD PMID:14583596 5-alpha-THDOC affects oxidation EXP 6480464 AKR1C1 protein affects the oxidation of tetrahydrodeoxycorticosterone CTD PMID:12604236 5-fluorouracil affects response to substance EXP 6480464 AKR1C1 protein affects the susceptibility to Fluorouracil CTD PMID:16217747 5-fluorouracil affects expression EXP 6480464 Fluorouracil affects the expression of AKR1C1 mRNA CTD PMID:16584549 5alpha-pregnane-3,20-dione affects reduction EXP 6480464 AKR1C1 protein affects the reduction of 5-alpha-Dihydroprogesterone CTD PMID:12604236 5alpha-pregnane-3,20-dione increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of 5-alpha-Dihydroprogesterone CTD PMID:11995921 7-hydroxyflavone multiple interactions EXP 6480464 7-hydroxyflavone binds to and results in decreased activity of AKR1C1 protein CTD PMID:16962702 9,10-phenanthroquinone increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of 9, 10-phenanthrenequinone CTD PMID:17950253 9,10-phenanthroquinone increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of 9, 10-phenanthrenequinone CTD PMID:16508162 9,10-phenanthroquinone increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of 9, 10-phenanthrenequinone CTD PMID:21851338 , PMID:23261716 9,10-phenanthroquinone multiple interactions EXP 6480464 AKR1C1 protein results in increased reduction of and affects the activity of 9, 10-phenanthrenequinone CTD PMID:21910479 9-cis-retinal increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of 9-cis-retinal CTD PMID:21851338 acenaphthoquinone increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of acenaphthenequinone CTD PMID:16508162 acetylsalicylic acid decreases activity EXP 6480464 Aspirin results in decreased activity of AKR1C1 protein CTD PMID:19010312 aflatoxin B1 decreases methylation EXP 6480464 Aflatoxin B1 results in decreased methylation of AKR1C1 gene CTD PMID:27153756 aflatoxin B1 decreases expression ISO RGD:1614979 6480464 Aflatoxin B1 results in decreased expression of AKR1C20 mRNA CTD PMID:19770486 aflatoxin B1 decreases expression ISO RGD:1306847 6480464 Aflatoxin B1 results in decreased expression of AKR1C1 mRNA CTD PMID:22484513 alpha-hexylcinnamaldehyde increases expression EXP 6480464 hexyl cinnamic aldehyde results in increased expression of AKR1C1 mRNA CTD PMID:20566472 amiodarone increases expression EXP 6480464 Amiodarone results in increased expression of AKR1C1 mRNA CTD PMID:21163907 anthranilic acid decreases activity EXP 6480464 anthranilic acid analog results in decreased activity of AKR1C1 protein CTD PMID:19007763 arsenite(3-) multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1C1 mRNA, SQSTM1 protein affects the reaction [[sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1C1 mRNA] CTD PMID:31781319 arsenous acid decreases response to substance EXP 6480464 AKR1C1 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 arsenous acid multiple interactions EXP 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA, Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to AKR1C1 protein] CTD PMID:25913414 , PMID:26598702 astilbin multiple interactions EXP 6480464 [astilbin co-treated with Cisplatin] results in increased expression of AKR1C1 mRNA CTD PMID:29471006 avobenzone increases expression EXP 6480464 avobenzone results in increased expression of AKR1C1 mRNA CTD PMID:31016361 azathioprine increases expression EXP 6480464 Azathioprine results in increased expression of AKR1C1 mRNA CTD PMID:22623647 Bandrowski's base increases expression EXP 6480464 Bandrowski's base results in increased expression of AKR1C1 mRNA CTD PMID:20566472 benzbromarone multiple interactions EXP 6480464 Benzbromarone binds to and results in decreased activity of AKR1C1 protein CTD PMID:12604236 Benzo[a]fluorene increases expression EXP 6480464 benzo(a)fluorene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 benzo[a]pyrene affects response to substance EXP 6480464 AKR1C1 protein affects the susceptibility to Benzo(a)pyrene CTD PMID:19800895 benzo[a]pyrene decreases expression ISO RGD:1614979 6480464 Benzo(a)pyrene results in decreased expression of AKR1C20 mRNA CTD PMID:19770486 benzo[a]pyrene increases expression EXP 6480464 Benzo(a)pyrene results in increased expression of AKR1C1 mRNA CTD PMID:15735009 more ... benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of AKR1C1 mRNA CTD PMID:16545412 benzo[a]pyrene multiple interactions EXP 6480464 [Butyric Acid co-treated with Benzo(a)pyrene] results in increased expression of AKR1C1 mRNA more ... CTD PMID:17612574 more ... Benzo[a]pyrene-7,8-diol multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7, 8-dihydrodiol CTD PMID:21910479 benzo[a]pyrene-7,8-dione multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7, 8-dione CTD PMID:21910479 benzo[a]pyrene-7,8-dione increases expression EXP 6480464 benzo(a)pyrene-7, 8-dione results in increased expression of AKR1C1 mRNA CTD PMID:9973208 benzo[b]fluoranthene increases expression EXP 6480464 benzo(b)fluoranthene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 Benzo[b]fluorene increases expression EXP 6480464 benzo(b)fluorene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 Benzo[k]fluoranthene increases expression EXP 6480464 benzo(k)fluoranthene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 benzoic acid increases expression EXP 6480464 Benzoic Acid results in increased expression of AKR1C1 mRNA CTD PMID:20566472 beta-naphthoflavone increases expression EXP 6480464 beta-Naphthoflavone results in increased expression of AKR1C1 mRNA CTD PMID:17253728 , PMID:32151702 bexarotene increases expression EXP 6480464 bexarotene results in increased expression of AKR1C1 mRNA CTD PMID:17178900 bis(2-ethylhexyl) phthalate increases expression EXP 6480464 Diethylhexyl Phthalate results in increased expression of AKR1C1 mRNA CTD PMID:28412506 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1614979 6480464 Diethylhexyl Phthalate results in decreased expression of AKR1C20 mRNA CTD PMID:28085963 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of AKR1C1 mRNA CTD PMID:30903817 bisphenol A decreases methylation EXP 6480464 bisphenol A results in decreased methylation of AKR1C1 gene CTD PMID:31601247 bisphenol A increases expression ISO RGD:1614979 6480464 bisphenol A results in increased expression of AKR1C20 mRNA CTD PMID:30245210 bisphenol A affects expression ISO RGD:1306847 6480464 bisphenol A affects the expression of AKR1C1 mRNA CTD PMID:30903817 bortezomib multiple interactions EXP 6480464 [arsenic trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA CTD PMID:25913414 bortezomib increases expression EXP 6480464 Bortezomib results in increased expression of AKR1C1 mRNA CTD PMID:21215737 bromosulfophthalein decreases activity ISO RGD:1614979 6480464 Sulfobromophthalein results in decreased activity of AKR1C20 protein CTD PMID:16508162 butyric acid multiple interactions EXP 6480464 [Butyric Acid co-treated with Benzo(a)pyrene] results in increased expression of AKR1C1 mRNA CTD PMID:30439556 cadmium atom increases expression EXP 6480464 Cadmium results in increased expression of AKR1C1 mRNA CTD PMID:21172416 cadmium atom multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of AKR1C1 mRNA CTD PMID:29741670 , PMID:31738976 cadmium dichloride multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of AKR1C1 mRNA CTD PMID:29741670 , PMID:31738976 cadmium dichloride decreases expression ISO RGD:1306847 6480464 Cadmium Chloride results in decreased expression of AKR1C1 mRNA CTD PMID:25993096 cadmium sulfate multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1C1 mRNA CTD PMID:18654764 calcitriol multiple interactions EXP 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of AKR1C1 mRNA CTD PMID:21592394 calcitriol increases expression EXP 6480464 Calcitriol results in increased expression of AKR1C1 mRNA CTD PMID:12040012 , PMID:21592394 carbon nanotube decreases expression ISO RGD:1614979 6480464 Nanotubes more ... CTD PMID:25620056 carmustine affects response to substance EXP 6480464 AKR1C1 mRNA affects the susceptibility to Carmustine CTD PMID:16365179 celastrol increases expression EXP 6480464 celastrol results in increased expression of AKR1C1 mRNA CTD PMID:17010675 CGP 52608 multiple interactions EXP 6480464 CGP 52608 promotes the reaction [RORA protein binds to AKR1C1 gene] CTD PMID:28238834 chenodeoxycholic acid decreases expression EXP 6480464 Chenodeoxycholic Acid results in decreased expression of AKR1C1 mRNA CTD PMID:27174168 chlorohydrocarbon multiple interactions ISO RGD:1306847 6480464 [Hydrocarbons, Chlorinated co-treated with Polychlorinated Biphenyls co-treated with methylmercuric chloride] results in decreased expression of AKR1C1 mRNA CTD PMID:30744511 chrysene increases expression EXP 6480464 chrysene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 ciglitazone multiple interactions EXP 6480464 [ciglitazone binds to PPARG protein alternative form] which results in increased expression of AKR1C1 mRNA, [ciglitazone binds to PPARG protein] which results in increased expression of AKR1C1 mRNA CTD PMID:16197558 cinnamyl alcohol increases expression EXP 6480464 cinnamyl alcohol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 cisplatin multiple interactions EXP 6480464 [astilbin co-treated with Cisplatin] results in increased expression of AKR1C1 mRNA more ... CTD PMID:23165153 more ... cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of AKR1C1 mRNA CTD PMID:23165153 , PMID:27392435 cisplatin decreases response to substance EXP 6480464 AKR1C1 protein results in decreased susceptibility to Cisplatin CTD PMID:20953859 , PMID:23165153 Clofop increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of fenofibric acid CTD PMID:27599626 cloxazolam decreases activity EXP 6480464 cloxazolam results in decreased activity of AKR1C1 protein CTD PMID:12604236 cobalt atom multiple interactions EXP 6480464 [tungsten carbide binds to Cobalt] which results in decreased expression of AKR1C1 mRNA CTD PMID:20105288 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of AKR1C1 mRNA CTD PMID:20105288 cobalt dichloride multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1C1 mRNA CTD PMID:18654764 coniferyl aldehyde multiple interactions EXP 6480464 NFE2L2 mutant form inhibits the reaction [coniferaldehyde results in increased expression of AKR1C1 protein] CTD PMID:26275128 coniferyl aldehyde increases expression EXP 6480464 coniferaldehyde results in increased expression of AKR1C1 mRNA, coniferaldehyde results in increased expression of AKR1C1 protein CTD PMID:26275128 copper atom multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1C1 mRNA CTD PMID:20971185 copper(0) multiple interactions EXP 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1C1 mRNA CTD PMID:20971185 copper(II) sulfate increases expression EXP 6480464 Copper Sulfate results in increased expression of AKR1C1 mRNA CTD PMID:19549813 coumarin decreases expression ISO RGD:1306847 6480464 coumarin results in decreased expression of AKR1C6 mRNA CTD PMID:18480146 crotonaldehyde increases expression EXP 6480464 2-butenal results in increased expression of AKR1C1 mRNA CTD PMID:20471460 cyclopentanol increases oxidation EXP 6480464 AKR1C1 protein results in increased oxidation of cyclopentanol CTD PMID:23261716 cyclopentanone increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of cyclopentanone CTD PMID:23261716 cyclopentanone multiple interactions EXP 6480464 NADP promotes the reaction [AKR1C1 protein results in increased reduction of cyclopentanone] CTD PMID:23261716 cyclosporin A increases expression EXP 6480464 Cyclosporine results in increased expression of AKR1C1 mRNA CTD PMID:25562108 cyclosporin A decreases expression ISO RGD:1614979 6480464 Cyclosporine results in decreased expression of AKR1C20 mRNA CTD PMID:19770486 dexamethasone increases expression EXP 6480464 Dexamethasone results in increased expression of AKR1C1 mRNA CTD PMID:25047013 dexamethasone multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of AKR1C1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AKR1C1 mRNA CTD PMID:28628672 diarsenic trioxide multiple interactions EXP 6480464 [Arsenic Trioxide co-treated with Bortezomib] results in increased expression of AKR1C1 mRNA, Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to AKR1C1 protein] CTD PMID:25913414 , PMID:26598702 diarsenic trioxide decreases response to substance EXP 6480464 AKR1C1 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 diazepam decreases activity EXP 6480464 Diazepam results in decreased activity of AKR1C1 protein CTD PMID:11995921 , PMID:12604236 Dibenz[a,c]anthracene increases expression EXP 6480464 benzotriphenylene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 dibenz[a,h]anthracene increases expression EXP 6480464 1 more ... CTD PMID:17253728 dibenzo[a,l]pyrene multiple interactions EXP 6480464 [Particulate Matter co-treated with dibenzo(a more ... CTD PMID:17612574 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of AKR1C1 mRNA CTD PMID:18214805 dicoumarol decreases activity ISO RGD:1306847 6480464 Dicumarol results in decreased activity of AKR1C6 protein CTD PMID:16788056 dienogest decreases expression EXP 6480464 dienogest results in decreased expression of AKR1C1 mRNA CTD PMID:23183084 diquat increases expression EXP 6480464 Diquat results in increased expression of AKR1C1 mRNA CTD PMID:21172416 disulfiram increases expression EXP 6480464 Disulfiram results in increased expression of AKR1C1 mRNA CTD PMID:20566472 diuron increases expression EXP 6480464 Diuron metabolite results in increased expression of AKR1C1 mRNA CTD PMID:24172598 dorsomorphin multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 dutasteride increases expression EXP 6480464 Dutasteride results in increased expression of AKR1C1 mRNA CTD PMID:16806904 dydrogesterone increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of Dydrogesterone CTD PMID:21182831 dydrogesterone increases expression EXP 6480464 Dydrogesterone results in increased expression of AKR1C1 mRNA CTD PMID:23183084 dydrogesterone decreases expression EXP 6480464 Dydrogesterone results in decreased expression of AKR1C1 mRNA CTD PMID:23183084 dydrogesterone decreases activity EXP 6480464 Dydrogesterone results in decreased activity of AKR1C1 protein CTD PMID:21182831 entinostat decreases expression EXP 6480464 entinostat results in decreased expression of AKR1C1 mRNA CTD PMID:27188386 estazolam decreases activity EXP 6480464 Estazolam results in decreased activity of AKR1C1 protein CTD PMID:11995921 etacrynic acid increases expression EXP 6480464 Ethacrynic Acid results in increased expression of AKR1C1 mRNA CTD PMID:9973208 ethyl methanesulfonate increases expression EXP 6480464 Ethyl Methanesulfonate results in increased expression of AKR1C1 mRNA CTD PMID:23649840 eugenol increases expression EXP 6480464 Eugenol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 farnesol increases expression EXP 6480464 Farnesol results in increased expression of AKR1C1 mRNA CTD PMID:30806763 fenamic acid decreases activity EXP 6480464 fenamic acid analog results in decreased activity of AKR1C1 protein CTD PMID:19010312 flufenamic acid multiple interactions EXP 6480464 Flufenamic Acid inhibits the reaction [AKR1C1 protein affects the susceptibility to oxaliplatin], Flufenamic Acid inhibits the reaction [AKR1C1 protein results in increased metabolism of Dihydrotestosterone] CTD PMID:14672942 , PMID:23933386 flufenamic acid decreases activity ISO RGD:1614979 6480464 Flufenamic Acid results in decreased activity of AKR1C20 protein CTD PMID:16508162 flufenamic acid decreases activity EXP 6480464 Flufenamic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 , PMID:8573067 flunitrazepam decreases activity EXP 6480464 Flunitrazepam results in decreased activity of AKR1C1 protein CTD PMID:11995921 flurbiprofen decreases activity EXP 6480464 Flurbiprofen results in decreased activity of AKR1C1 protein CTD PMID:19010312 flutamide decreases expression ISO RGD:1306847 6480464 Flutamide results in decreased expression of AKR1C1 mRNA CTD PMID:24136188 folic acid increases expression ISO RGD:1614979 6480464 Folic Acid results in increased expression of AKR1C20 mRNA CTD PMID:25629700 furan decreases expression ISO RGD:1306847 6480464 furan results in decreased expression of AKR1C1 mRNA CTD PMID:25539665 gamma-linolenic acid increases expression EXP 6480464 gamma-Linolenic Acid results in increased expression of AKR1C1 mRNA CTD PMID:20664735 gedunin increases expression EXP 6480464 gedunin results in increased expression of AKR1C1 mRNA CTD PMID:17010675 genistein decreases activity ISO RGD:1306847 6480464 Genistein results in decreased activity of AKR1C6 protein CTD PMID:16788056 geraniol increases expression EXP 6480464 geraniol results in increased expression of AKR1C1 mRNA CTD PMID:30806763 glafenine decreases expression ISO RGD:1306847 6480464 Glafenine results in decreased expression of AKR1C1 mRNA CTD PMID:24136188 glimepiride decreases activity EXP 6480464 glimepiride results in decreased activity of AKR1C1 protein CTD PMID:26362498 glipizide decreases activity EXP 6480464 Glipizide results in decreased activity of AKR1C1 protein CTD PMID:26362498 glyburide decreases activity EXP 6480464 Glyburide results in decreased activity of AKR1C1 protein CTD PMID:26362498 glycyrrhetinate decreases activity EXP 6480464 Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 glycyrrhetinic acid decreases activity EXP 6480464 Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 hexane increases expression EXP 6480464 n-hexane results in increased expression of AKR1C1 mRNA CTD PMID:20566472 hexestrol decreases activity EXP 6480464 Hexestrol results in decreased activity of AKR1C1 protein CTD PMID:12604236 , PMID:8573067 hexestrol decreases activity ISO RGD:1614979 6480464 Hexestrol results in decreased activity of AKR1C20 protein CTD PMID:16508162 hydrogen peroxide increases expression EXP 6480464 Hydrogen Peroxide results in increased expression of AKR1C1 mRNA CTD PMID:9973208 hydrogen peroxide decreases expression EXP 6480464 Hydrogen Peroxide results in decreased expression of AKR1C1 protein CTD PMID:34581912 hydrogen peroxide multiple interactions EXP 6480464 [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species] which results in increased expression of AKR1C1 mRNA, [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species] which results in increased expression of AKR1C1 protein CTD PMID:19320734 ibuprofen decreases activity EXP 6480464 Ibuprofen results in decreased activity of AKR1C1 protein CTD PMID:19010312 Indeno[1,2,3-cd]pyrene increases expression EXP 6480464 indeno(1 more ... CTD PMID:17253728 indometacin decreases activity EXP 6480464 Indomethacin results in decreased activity of AKR1C1 protein CTD PMID:12604236 more ... indometacin decreases activity ISO RGD:1614979 6480464 Indomethacin results in decreased activity of AKR1C20 protein CTD PMID:16508162 indometacin multiple interactions EXP 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of AKR1C1 mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of AKR1C1 mRNA CTD PMID:28628672 isoeugenol increases expression EXP 6480464 isoeugenol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 ivermectin decreases expression EXP 6480464 Ivermectin results in decreased expression of AKR1C1 protein CTD PMID:32959892 lead diacetate increases expression EXP 6480464 lead acetate results in increased expression of AKR1C1 mRNA CTD PMID:22839698 lead(0) affects splicing EXP 6480464 Lead affects the splicing of AKR1C1 mRNA CTD PMID:28903495 lead(2+) affects splicing EXP 6480464 Lead affects the splicing of AKR1C1 mRNA CTD PMID:28903495 lead(II) chloride increases expression EXP 6480464 lead chloride results in increased expression of AKR1C1 mRNA CTD PMID:18654764 lead(II) chloride multiple interactions EXP 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1C1 mRNA CTD PMID:18654764 leflunomide decreases expression EXP 6480464 leflunomide results in decreased expression of AKR1C1 mRNA CTD PMID:28988120 leflunomide decreases expression ISO RGD:1306847 6480464 Leflunomide results in decreased expression of AKR1C1 mRNA CTD PMID:24136188 lithocholic acid affects binding EXP 6480464 AKR1C1 protein binds to Lithocholic Acid CTD PMID:8573067 lithocholic acid decreases activity EXP 6480464 Lithocholic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 , PMID:8573067 malathion increases expression EXP 6480464 Malathion results in increased expression of AKR1C1 mRNA CTD PMID:16079077 , PMID:18214805 meclofenamic acid decreases activity EXP 6480464 Meclofenamic Acid results in decreased activity of AKR1C1 protein CTD PMID:19010312 more ... Medazepam decreases activity EXP 6480464 Medazepam results in decreased activity of AKR1C1 protein CTD PMID:11995921 , PMID:12604236 medroxyprogesterone acetate decreases activity EXP 6480464 Medroxyprogesterone Acetate results in decreased activity of AKR1C1 protein CTD PMID:12604236 , PMID:21182831 medroxyprogesterone acetate increases expression EXP 6480464 Medroxyprogesterone Acetate results in increased expression of AKR1C1 mRNA CTD PMID:18497975 , PMID:23183084 medroxyprogesterone acetate decreases expression EXP 6480464 Medroxyprogesterone Acetate results in decreased expression of AKR1C1 mRNA CTD PMID:23183084 mefenamic acid decreases activity EXP 6480464 Mefenamic Acid analog results in decreased activity of AKR1C1 protein CTD PMID:19010312 menadione affects expression EXP 6480464 Vitamin K 3 affects the expression of AKR1C1 mRNA CTD PMID:20044591 mercury dibromide increases expression EXP 6480464 mercuric bromide results in increased expression of AKR1C1 mRNA CTD PMID:26272509 mercury dibromide multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 methyl methanesulfonate increases expression EXP 6480464 Methyl Methanesulfonate results in increased expression of AKR1C1 mRNA CTD PMID:23649840 methyl salicylate increases expression EXP 6480464 methyl salicylate results in increased expression of AKR1C1 mRNA CTD PMID:20566472 methylmercury chloride increases expression EXP 6480464 methylmercuric chloride results in increased expression of AKR1C1 mRNA CTD PMID:28001369 methylmercury chloride multiple interactions ISO RGD:1306847 6480464 [Hydrocarbons, Chlorinated co-treated with Polychlorinated Biphenyls co-treated with methylmercuric chloride] results in decreased expression of AKR1C1 mRNA CTD PMID:30744511 monosodium L-glutamate increases expression ISO RGD:1614979 6480464 Sodium Glutamate results in increased expression of AKR1C20 mRNA CTD PMID:25473020 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal multiple interactions EXP 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Salicylic Acid inhibits the reaction [AKR1C1 protein results in decreased susceptibility to Cisplatin]] CTD PMID:23165153 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression EXP 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1C1 mRNA CTD PMID:21215737 , PMID:23165153 N-nitrosodiethylamine multiple interactions ISO RGD:1306847 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of AKR1C6 mRNA CTD PMID:28943392 N-nitrosodimethylamine decreases expression ISO RGD:1306847 6480464 Dimethylnitrosamine results in decreased expression of AKR1C1 mRNA CTD PMID:25380136 NAD zwitterion multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol more ... CTD PMID:25446855 NAD(+) multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NAD] results in increased oxidation of acenaphthene-1-ol more ... CTD PMID:25446855 NADP zwitterion multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7 more ... CTD PMID:21910479 , PMID:23261716 NADP(+) multiple interactions EXP 6480464 [AKR1C1 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7 more ... CTD PMID:21910479 , PMID:23261716 naproxen decreases activity EXP 6480464 Naproxen results in decreased activity of AKR1C1 protein CTD PMID:19010312 nefazodone decreases expression ISO RGD:1306847 6480464 nefazodone results in decreased expression of AKR1C1 mRNA CTD PMID:24136188 neoastilbin multiple interactions EXP 6480464 [astilbin co-treated with Cisplatin] results in increased expression of AKR1C1 mRNA CTD PMID:29471006 nickel sulfate increases expression EXP 6480464 nickel sulfate results in increased expression of AKR1C1 mRNA CTD PMID:20566472 nitrazepam decreases activity EXP 6480464 Nitrazepam results in decreased activity of AKR1C1 protein CTD PMID:11995921 norethisterone decreases activity EXP 6480464 Norethindrone results in decreased activity of AKR1C1 protein CTD PMID:21182831 ochratoxin A decreases expression EXP 6480464 ochratoxin A results in decreased expression of AKR1C1 mRNA CTD PMID:19287073 , PMID:32905824 octadecanoic acid increases expression EXP 6480464 stearic acid results in increased expression of AKR1C1 mRNA CTD PMID:32347412 octyl gallate decreases activity EXP 6480464 octyl gallate results in decreased activity of AKR1C1 protein CTD PMID:27163852 oxaliplatin multiple interactions EXP 6480464 alpha-methylcinnamic acid inhibits the reaction [AKR1C1 protein affects the susceptibility to oxaliplatin] more ... CTD PMID:23933386 oxaliplatin affects response to substance EXP 6480464 AKR1C1 protein affects the susceptibility to oxaliplatin CTD PMID:23933386 oxcarbazepine increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of oxcarbazepine CTD PMID:25063510 p-chloromercuribenzoic acid increases expression EXP 6480464 p-Chloromercuribenzoic Acid results in increased expression of AKR1C1 mRNA CTD PMID:26272509 p-chloromercuribenzoic acid multiple interactions EXP 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of AKR1C1 mRNA CTD PMID:26690555 paracetamol affects expression ISO RGD:1614979 6480464 Acetaminophen affects the expression of AKR1C20 mRNA CTD PMID:17562736 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of AKR1C1 mRNA CTD PMID:21420995 Paraoxon-methyl increases expression EXP 6480464 methylparaoxon results in increased expression of AKR1C1 mRNA CTD PMID:19800895 Paraoxon-methyl multiple interactions EXP 6480464 AKR1C1 protein affects the susceptibility to [Benzo(a)pyrene co-treated with methylparaoxon] CTD PMID:19800895 parathion-methyl multiple interactions EXP 6480464 AKR1C1 protein affects the susceptibility to [Benzo(a)pyrene co-treated with Methyl Parathion] more ... CTD PMID:19800895 parathion-methyl increases expression EXP 6480464 Methyl Parathion results in increased expression of AKR1C1 mRNA CTD PMID:19800895 parathion-methyl increases activity EXP 6480464 Methyl Parathion results in increased activity of AKR1C1 protein CTD PMID:19800895 PCB138 multiple interactions ISO RGD:1614979 6480464 [2 more ... CTD PMID:25510870 pentachlorophenol increases expression ISO RGD:1614979 6480464 Pentachlorophenol results in increased expression of AKR1C20 mRNA CTD PMID:23892564 perfluorooctanoic acid decreases expression EXP 6480464 perfluorooctanoic acid results in decreased expression of AKR1C1 mRNA CTD PMID:23978341 perfluorooctanoic acid affects expression ISO RGD:1614979 6480464 perfluorooctanoic acid affects the expression of AKR1C20 mRNA CTD PMID:18281256 phenethyl caffeate decreases activity EXP 6480464 caffeic acid phenethyl ester results in decreased activity of AKR1C1 protein CTD PMID:27163852 phenobarbital multiple interactions ISO RGD:1614979 6480464 NR1I3 protein affects the reaction [Phenobarbital results in increased expression of AKR1C20 mRNA] CTD PMID:19482888 phenobarbital increases expression ISO RGD:1614979 6480464 Phenobarbital results in increased expression of AKR1C20 mRNA CTD PMID:19482888 phenolphthalein multiple interactions EXP 6480464 Phenolphthalein inhibits the reaction [AKR1C1 protein affects the susceptibility to oxaliplatin] CTD PMID:23933386 phenolphthalein decreases activity EXP 6480464 Phenolphthalein results in decreased activity of AKR1C1 protein CTD PMID:12604236 phenylmercury acetate increases expression EXP 6480464 Phenylmercuric Acetate results in increased expression of AKR1C1 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions EXP 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 pirinixic acid multiple interactions EXP 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of AKR1C1 mRNA CTD PMID:19710929 pirinixic acid multiple interactions ISO RGD:1614979 6480464 [pirinixic acid co-treated with PPARA] results in decreased expression of AKR1C20 mRNA CTD PMID:20813756 pirinixic acid decreases expression ISO RGD:1614979 6480464 pirinixic acid results in decreased expression of AKR1C20 mRNA CTD PMID:18445702 , PMID:20813756 pirinixic acid decreases expression ISO RGD:1306847 6480464 pirinixic acid results in decreased expression of AKR1C1 mRNA CTD PMID:22484513 potassium dichromate increases expression ISO RGD:1614979 6480464 Potassium Dichromate results in increased expression of AKR1C20 mRNA CTD PMID:23608068 pregnenolone 16alpha-carbonitrile decreases expression ISO RGD:1614979 6480464 Pregnenolone Carbonitrile results in decreased expression of AKR1C20 mRNA CTD PMID:28903501 progesterone multiple interactions EXP 6480464 AKR1C1 protein affects the metabolism of and results in decreased activity of Progesterone CTD PMID:16962702 progesterone decreases expression EXP 6480464 Progesterone results in decreased expression of AKR1C1 mRNA CTD PMID:23183084 progesterone increases reduction EXP 6480464 AKR1C1 protein results in increased reduction of Progesterone CTD PMID:11995921 , PMID:22245609 progesterone affects reduction EXP 6480464 AKR1C1 protein affects the reduction of Progesterone CTD PMID:12604236 , PMID:16338060 propan-2-ol increases expression EXP 6480464 2-Propanol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 prostaglandin G2 increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of prostaglandin G2 CTD PMID:8573067 pyrimidine decreases activity EXP 6480464 pyrimidine analog results in decreased activity of AKR1C1 protein CTD PMID:19007763 quercetin decreases activity ISO RGD:1306847 6480464 Quercetin results in decreased activity of AKR1C6 protein CTD PMID:16788056 quinolin-8-ol increases expression EXP 6480464 Oxyquinoline results in increased expression of AKR1C1 mRNA CTD PMID:21632981 quinomethionate increases expression EXP 6480464 quinomethionate results in increased expression of AKR1C1 mRNA CTD PMID:18214805 quinomethionate affects expression EXP 6480464 quinomethionate affects the expression of AKR1C1 mRNA CTD PMID:15387888 rac-lactic acid increases expression EXP 6480464 Lactic Acid results in increased expression of AKR1C1 mRNA CTD PMID:20566472 , PMID:30851411 reactive oxygen species multiple interactions EXP 6480464 [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species] which results in increased expression of AKR1C1 mRNA, [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species] which results in increased expression of AKR1C1 protein CTD PMID:19320734 reactive oxygen species increases expression EXP 6480464 Reactive Oxygen Species results in increased expression of AKR1C1 mRNA CTD PMID:9973208 resorcinol increases expression EXP 6480464 resorcinol results in increased expression of AKR1C1 mRNA CTD PMID:30806763 rotenone decreases expression ISO RGD:1306847 6480464 Rotenone results in decreased expression of AKR1C1 mRNA CTD PMID:28374803 salicylic acid multiple interactions EXP 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Salicylic Acid inhibits the reaction [AKR1C1 protein results in decreased susceptibility to Cisplatin]], Salicylic Acid inhibits the reaction [AKR1C1 protein results in decreased susceptibility to Cisplatin] CTD PMID:23165153 salicylic acid decreases activity EXP 6480464 Salicylic Acid results in decreased activity of AKR1C1 protein CTD PMID:19010312 , PMID:23165153 SB 431542 multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide decreases expression EXP 6480464 Silicon Dioxide analog results in decreased expression of AKR1C1 mRNA CTD PMID:25895662 silicon dioxide increases expression ISO RGD:1614979 6480464 Silicon Dioxide results in increased expression of AKR1C1 mRNA, Silicon Dioxide results in increased expression of AKR1C1 protein CTD PMID:30698894 silicon dioxide multiple interactions ISO RGD:1614979 6480464 [Silicon Dioxide co-treated with Vitamin D] results in increased expression of AKR1C1 mRNA, [Silicon Dioxide co-treated with Vitamin D] results in increased expression of AKR1C1 protein CTD PMID:30698894 silver atom increases expression EXP 6480464 Silver results in increased expression of AKR1C1 mRNA CTD PMID:22036727 silver atom multiple interactions EXP 6480464 NFE2L2 protein promotes the reaction [Silver results in increased expression of AKR1C1 mRNA] CTD PMID:22036727 silver(0) increases expression EXP 6480464 Silver results in increased expression of AKR1C1 mRNA CTD PMID:22036727 silver(0) multiple interactions EXP 6480464 NFE2L2 protein promotes the reaction [Silver results in increased expression of AKR1C1 mRNA] CTD PMID:22036727 simvastatin increases expression EXP 6480464 Simvastatin results in increased expression of AKR1C1 mRNA CTD PMID:17428261 sodium arsenate increases expression EXP 6480464 sodium arsenate results in increased expression of AKR1C1 mRNA CTD PMID:12727804 sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of AKR1C1 mRNA, sodium arsenite results in increased expression of AKR1C1 protein CTD PMID:19696165 more ... sodium arsenite multiple interactions EXP 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1C1 mRNA, SQSTM1 protein affects the reaction [[sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1C1 mRNA] CTD PMID:31781319 sodium arsenite affects expression EXP 6480464 sodium arsenite affects the expression of AKR1C1 mRNA CTD PMID:29319823 sodium dichromate decreases expression ISO RGD:1306847 6480464 sodium bichromate results in decreased expression of AKR1C1 mRNA CTD PMID:25993096 sodium dodecyl sulfate increases expression EXP 6480464 Sodium Dodecyl Sulfate results in increased expression of AKR1C1 mRNA CTD PMID:20566472 sulforaphane increases expression EXP 6480464 sulforaphane results in increased expression of AKR1C1 mRNA CTD PMID:24383545 more ... sulforaphane multiple interactions EXP 6480464 NFE2L2 protein affects the reaction [sulforaphane results in increased expression of AKR1C1 mRNA] CTD PMID:31518892 sulindac decreases activity EXP 6480464 Sulindac results in decreased activity of AKR1C1 protein CTD PMID:19010312 sulindac sulfide increases expression EXP 6480464 sulindac sulfide results in increased expression of AKR1C1 mRNA CTD PMID:16184548 sunitinib decreases expression EXP 6480464 Sunitinib results in decreased expression of AKR1C1 mRNA CTD PMID:31533062 tamoxifen decreases expression ISO RGD:1614979 6480464 Tamoxifen results in decreased expression of AKR1C20 mRNA CTD PMID:25123088 temozolomide affects response to substance EXP 6480464 AKR1C1 mRNA affects the susceptibility to temozolomide CTD PMID:16365179 tert-butyl hydroperoxide increases expression EXP 6480464 tert-Butylhydroperoxide results in increased expression of AKR1C1 mRNA CTD PMID:15336504 testosterone multiple interactions EXP 6480464 [Testosterone co-treated with Calcitriol] results in increased expression of AKR1C1 mRNA CTD PMID:21592394 testosterone increases metabolic processing ISO RGD:1614979 6480464 AKR1C20 protein results in increased metabolism of Testosterone CTD PMID:16508162 testosterone increases oxidation ISO RGD:1306847 6480464 AKR1C6 protein results in increased oxidation of Testosterone CTD PMID:16788056 testosterone increases expression EXP 6480464 Testosterone results in increased expression of AKR1C1 mRNA CTD PMID:21592394 testosterone enanthate affects expression EXP 6480464 testosterone enanthate affects the expression of AKR1C1 mRNA CTD PMID:17440010 tetrachloromethane decreases expression ISO RGD:1614979 6480464 Carbon Tetrachloride results in decreased expression of AKR1C20 mRNA CTD PMID:27339419 , PMID:31919559 tetraphene increases expression EXP 6480464 benz(a)anthracene results in increased expression of AKR1C1 mRNA CTD PMID:17253728 , PMID:22236718 thioacetamide multiple interactions ISO RGD:1306847 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in decreased expression of AKR1C6 mRNA CTD PMID:28943392 thioacetamide decreases expression ISO RGD:1306847 6480464 Thioacetamide results in decreased expression of AKR1C1 mRNA CTD PMID:23411599 more ... tofacitinib increases metabolic processing EXP 6480464 AKR1C1 protein results in increased metabolism of tofacitinib metabolite CTD PMID:27117606 tolcapone affects binding ISO RGD:1306847 6480464 Tolcapone binds to AKR1C1 protein CTD PMID:19783845 trans-isoeugenol increases expression EXP 6480464 isoeugenol results in increased expression of AKR1C1 mRNA CTD PMID:20566472 trichloroethene increases methylation ISO RGD:1306847 6480464 Trichloroethylene results in increased methylation of AKR1C1 gene CTD PMID:27618143 trichostatin A increases expression EXP 6480464 trichostatin A results in increased expression of AKR1C1 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions EXP 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 triclosan decreases expression EXP 6480464 Triclosan results in decreased expression of AKR1C1 mRNA CTD PMID:30510588 tris(2-butoxyethyl) phosphate decreases expression EXP 6480464 tris(2-butoxyethyl) phosphate results in decreased expression of AKR1C1 mRNA CTD PMID:29024780 Tungsten carbide decreases expression EXP 6480464 tungsten carbide results in decreased expression of AKR1C1 mRNA CTD PMID:20105288 Tungsten carbide multiple interactions EXP 6480464 [tungsten carbide binds to Cobalt] which results in decreased expression of AKR1C1 mRNA CTD PMID:20105288 urethane decreases expression EXP 6480464 Urethane results in decreased expression of AKR1C1 mRNA CTD PMID:28818685 ursodeoxycholic acid decreases activity EXP 6480464 Ursodeoxycholic Acid results in decreased activity of AKR1C1 protein CTD PMID:12604236 valdecoxib decreases expression ISO RGD:1306847 6480464 valdecoxib results in decreased expression of AKR1C1 mRNA CTD PMID:24136188 valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of AKR1C1 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions EXP 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 vancomycin increases expression ISO RGD:1614979 6480464 Vancomycin results in increased expression of AKR1C20 mRNA CTD PMID:18930951 vitamin D increases expression EXP 6480464 Vitamin D results in increased expression of AKR1C1 mRNA, Vitamin D results in increased expression of AKR1C1 protein CTD PMID:30698894 vitamin D increases expression ISO RGD:1614979 6480464 Vitamin D results in increased expression of AKR1C1 mRNA, Vitamin D results in increased expression of AKR1C1 protein CTD PMID:30698894 vitamin D multiple interactions ISO RGD:1614979 6480464 [Particulate Matter co-treated with Vitamin D] results in increased expression of AKR1C1 mRNA more ... CTD PMID:30698894 vorinostat multiple interactions EXP 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1C1 mRNA CTD PMID:27188386 vorinostat increases expression EXP 6480464 vorinostat results in increased expression of AKR1C1 mRNA CTD PMID:26272509 zinc atom multiple interactions EXP 6480464 [PCI 5002 co-treated with Zinc] results in decreased expression of AKR1C1 mRNA CTD PMID:18593933 zinc(0) multiple interactions EXP 6480464 [PCI 5002 co-treated with Zinc] results in decreased expression of AKR1C1 mRNA CTD PMID:18593933 zomepirac decreases activity EXP 6480464 zomepirac results in decreased activity of AKR1C1 protein CTD PMID:19010312
